Market Overview

UPDATE: Cantor Fitzgerald Initiates Jazz Pharmaceuticals at Buy on Xyrem Outlook

Share:
Related JAZZ
The Wall Street Research Making Waves Today
Jazz Pharma Could Be Worth Over $200 If Xyrem Adds Long-Term Value: Here's How
Premarket Biotech Digest: Natural Killer Cells, Lipocine NDA, FDA Calendar (Seeking Alpha)

Cantor Fitzgerald initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and $86.00 price target.

Cantor Fitzgerald said, "We see Jazz as an attractive growth story that has been held back by what we view as unreasonable generic concerns over its key revenue driver, Xyrem (a drug used for the treatment of narcolepsy that represents 69% of revenue). Jazz is poised to deliver +39% Y/Y revenue growth in 2013, and we believe that double-digit top line growth is sustainable through 2016. On the bottom line, Jazz benefits from its Irish tax rate (cash tax is in the high teens) and significant operational leverage. Management has indicated that it plans to acquire additional on-market or late stage assets in 2013 after completing significant transactions in both 2011 and 2012, which could create major momentum for the stock."

Jazz Pharmaceuticals closed at $58.50 on Friday.

Latest Ratings for JAZZ

DateFirmActionFromTo
Jul 2015Leerink SwannMaintainsOutperform
Jun 2015UBSMaintainsBuy
May 2015Leerink SwannMaintainsOutperform

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Initiation Analyst Ratings

 

Related Articles (JAZZ)

Get Benzinga's Newsletters